NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS

NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS

Detalhes bibliográficos
Main Authors:	Goodman, A, O'Hara, G, Ewer, K, Collins, K, Edwards, N, Reyes-Sandoval, A, Lawrie, A, Nicosia, A, Colloca, S, Gilbert, S, Hill, A
Formato:	Conference item
Publicado em:	2009

Registos relacionados

EVALUATION OF SIMIAN ADENOVIRAL VECTOR ADCH63 EXPRESSING MSP-1 AS A CANDIDATE BLOOD-STAGE MALARIA VACCINE
Por: Goodman, A, et al.
Publicado em: (2009)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
Por: Capone, S, et al.
Publicado em: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
Por: Capone, S, et al.
Publicado em: (2010)

HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1 CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN VOLUNTEERS
Por: Sheehy, S, et al.
Publicado em: (2010)

Immunogenicity of a pre-erythrocytic-stage malaria insert ME-trap encoded by novel simian adenoviral vectors
Por: Reyes-Sandoval, A, et al.
Publicado em: (2005)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
Por: O'Hara, G, et al.
Publicado em: (2012)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
Por: Bliss, C, et al.
Publicado em: (2016)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Por: Ogwang, C, et al.
Publicado em: (2013)

Quantifying Adenoviral Titers by Spectrophotometry
Por: S.J. O’Carroll, et al.
Publicado em: (2000-03-01)

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
Por: Reyes-Sandoval, A, et al.
Publicado em: (2008)

Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
Por: Reyes-Sandoval, A, et al.
Publicado em: (2011)

Prime-boost vectored malaria vaccines: progress and prospects.
Por: Hill, A, et al.
Publicado em: (2010)

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
Por: Fitzgerald, J, et al.
Publicado em: (2003)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
Por: Folegatti, PM, et al.
Publicado em: (2019)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
Por: Hodgson, S, et al.
Publicado em: (2014)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Por: Caroline Ogwang, et al.
Publicado em: (2013-01-01)

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Por: Bliss, C, et al.
Publicado em: (2018)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
Por: Ewer (nee Russell), K, et al.
Publicado em: (2017)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
Por: Hodgson, SH, et al.
Publicado em: (2014)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
Por: Reyes-Sandoval, A, et al.
Publicado em: (2010)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Por: Mensah, V, et al.
Publicado em: (2016)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
Por: Reyes-Sandoval, A, et al.
Publicado em: (2011)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)
Por: Reyes-Sandoval, A, et al.
Publicado em: (2011)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Por: Sheehy, S, et al.
Publicado em: (2012)

Low titer lentiviral transgenesis in rodents with simian immundeficiency virus vector
Por: Balázs Bender, et al.
Publicado em: (2013-09-01)

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
Por: Colloca, S, et al.
Publicado em: (2012)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Por: Victorine A Mensah, et al.
Publicado em: (2016-01-01)

New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
Por: Goodman, A, et al.
Publicado em: (2010)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
Por: De Barra, E, et al.
Publicado em: (2014)

Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
Por: Alessandra Vitelli, et al.
Publicado em: (2017-12-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Por: Tiono, AB, et al.
Publicado em: (2018)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Por: Kimani, D, et al.
Publicado em: (2014)

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.
Por: Reyes-Sandoval, A, et al.
Publicado em: (2004)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
Por: Sheehy, S, et al.
Publicado em: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Por: Sheehy, S, et al.
Publicado em: (2011)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Por: Morter, R, et al.
Publicado em: (2022)

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes
Por: von Delft, A, et al.
Publicado em: (2017)

Simian adenoviruses as vaccine vectors
Por: Morris, S, et al.
Publicado em: (2016)

Simian adenoviruses as vaccine vectors
Por: Morris, S, et al.
Publicado em: (2016)

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
Por: Rampling, T, et al.
Publicado em: (2018)